This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Harbour Biomed (Shanghai) Co., Ltd.. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: Yuqiang Shen: Innovator in Monoclonal Antibodies
Introduction
Yuqiang Shen is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biotechnology. He holds two patents that focus on the development of monoclonal antibodies, which have important applications in treating various diseases.
Latest Patents
Yuqiang Shen's latest patents include innovative isolated monoclonal antibodies that specifically bind to human CD152, also known as CTLA-4. These antibodies are designed to be used in methods for treating diseases, including cancers and autoimmune disorders. The patents detail the processes for making these antibodies and their potential therapeutic uses.
Career Highlights
Throughout his career, Yuqiang Shen has worked with notable companies in the biotechnology sector, including Harbour Biomed (Shanghai) Co., Ltd. and Harbour Biomed Co., Ltd. His work has significantly advanced the understanding and application of monoclonal antibodies in medical treatments.
Collaborations
Yuqiang Shen has collaborated with several professionals in his field, including colleagues Xin Gan and Yun He. These collaborations have contributed to the successful development of his patented technologies.
Conclusion
Yuqiang Shen's innovative work in monoclonal antibodies positions him as a key figure in biotechnology, with the potential to impact the treatment of serious diseases. His contributions continue to shape the future of medical therapies.